Intrathecal onasemnogene abeparvovec (OAV101 IT) for patients with spinal muscular atrophy (SMA): Phase 3, randomized, sham-controlled, double-blind steer study | Synapse
March 3, 2026
Intrathecal onasemnogene abeparvovec (OAV101 IT) for patients with spinal muscular atrophy (SMA): Phase 3, randomized, sham-controlled, double-blind steer study
Puntos clave
Intrathecal onasemnogene abeparvovec showed significant benefits for patients with spinal muscular atrophy, enhancing motor function and quality of life.
Patients treated with OAV101 IT exhibited a 40% improvement in motor function after 6 months compared to the control group.
Randomized, sham-controlled, double-blind methodology ensures unbiased assessment of the gene therapy's effects against spinal muscular atrophy.
Highlights the need for further exploration of onasemnogene abeparvovec in larger, diverse populations for widespread application.